MedTrace Logo

Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease

NCT00501111 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 659

Last updated 2014-07-23

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in future trials.

Conditions

  • Alzheimer Disease

Interventions

DRUG

AZD3480

3 oral doses

DRUG

Donepezil

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca AZD3480, Medical Science Director · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Romania
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501111 on ClinicalTrials.gov